DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum

Information source: University Hospital, Tours
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cystic Fibrosis

Intervention: Pulmozyme (Drug)

Phase: Phase 4

Status: Not yet recruiting

Sponsored by: University Hospital, Tours

Official(s) and/or principal investigator(s):
Patrice DIOT, PHD, Principal Investigator, Affiliation: University Hospital, Tours

Overall contact:
Patrice DIOT, PHD, Email: diot@med.univ-tours.fr

Summary

Serine proteases belonging to the elastase family are mainly responsible for lung tissue destruction as observed during cystic fibrosis. But anti-inflammatory therapies based on systemic or aerosolized protease-inhibitors administration, have not given the expected results until now. One reason would be the impaired access of therapeutic inhibitors to their molecular targets. It was recently shown that neutrophils actively secrete neutrophil extracellular traps (NETs) made of DNA that binds cationic proteases among other molecules. NETs together with DNA passively released from dead neutrophils contribute to the viscosity of CF expectorations which explains that rhDNase treatment fluidifies expectorations and improves the patient status. Preliminary experiments in our laboratory have shown that DNA degradation was associated with a significant increase of proteolytic activity in the sputum soluble fraction. However the efficacy of exogenous inhibitors is also improved in these conditions. Using the specific substrates and methodologies that we developed previously to measure cell-surface associated proteolytic activities, we will study the effects of DNase on the activity of individual proteases, their biodistribution in sputum and their regulation by potential therapeutic inhibitors. Enzymatic, immunochemical and microscopic (confocal and scanning) techniques will first be used for ex vivo studies on sputa freshly collected at the adult and paediatric CRCM in Tours, then on sputa from patients before and after administration of aerosolized rhDNase. We hypothesize that a better understanding of the biodistribution of neutrophil serine proteases and especially their binding to DNA will help designing new therapeutic strategies that facilitate inhibitor access to their protease targets.

Clinical Details

Official title: RhDNase Effect on Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum

Study design: Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: The biodistribution of elastase, Protease 3 and cathepsine G in the expectorations will be measured by the management report of these proteases between the freezing fractionand the soluble fraction, before and after rhDNase administration.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- cystic fibrosis disease

- with rhDNase treatment

Exclusion Criteria:

- Acute push of the bronchopulmonary attack or hospitalization for treatment of the

disease during 2 weeks previous

- Exposure to a antibiotherapy or treatment by corticoids

Locations and Contacts

Patrice DIOT, PHD, Email: diot@med.univ-tours.fr

University Hospital - Tours, Tours, France; Not yet recruiting
Patrice DIOT, PHD, Email: diot@med.univ-tours.fr
Pascaline Rameau, Email: rameau@med.univ-tours.fr
Patrice DIOT, PHD, Principal Investigator
Francoise Varaigne, MD, Sub-Investigator
Additional Information


Last updated: February 12, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017